Clinical Trials Browser

Cholangiocarcinoma

Gastrointestinal Stromal Tumors

Pancreatic Neoplasms

Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms

Neoplasm Metastasis, Endometrial Neoplasms

Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Eosinophilia, Myeloproliferative Disorders

Acrocephalosyndactylia

Acrocephalosyndactylia, Carcinoma, Transitional Cell, Neoplasm Metastasis

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Acrocephalosyndactylia, Carcinoma, Transitional Cell

Acrocephalosyndactylia, Cholangiocarcinoma

Acrocephalosyndactylia, Carcinoma, Non-Small-Cell Lung, Recurrence

Carcinoma, Transitional Cell

Cholangiocarcinoma

Advanced Malignancies

Breast Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Lung Neoplasms, Sarcoma, Stomach Neoplasms

Cholangiocarcinoma

Hematologic Neoplasms

Cholangiocarcinoma

Advanced Non Small Cell Lung Cancer

Colorectal Neoplasms

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

Locally Advanced Unresectable Gastric Cancer

Pancreatic Neoplasms

Carcinoma, Digestive System Neoplasms, Cholangiocarcinoma

Gastrointestinal Neoplasms

Gastrointestinal Neoplasms

Breast Neoplasms

Neoplasm Metastasis

Advanced Non-Small Cell Lung Cancer

Colorectal Neoplasms

Clinical Trials

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

PEMIGIST

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

FIGHT-209

POD1UM-204

Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

FIGHT-210

PEGASUS

Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements

The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor

Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma

FINPROVE

Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement

Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

ROME

Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR Variant

Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations

A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer (Excluding Biliary Tract Cancer) Patients With FGFR Alterations Who Have Failed Standard Therapy

A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations

Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)

A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy

A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy